Previous Article | Next Article ![]()
Journal of Virology, May 2000, p. 4258-4263, Vol. 74, No. 9
Center for Tropical Diseases and Department of Pathology,
University of Texas Medical Branch, Galveston, Texas
77555-0609,1 and Division of
Vector-Borne Infectious Diseases, National Center for Infectious
Diseases, Centers for Disease Control and Prevention, Public Health
Service, U.S. Department of Health and Human Services, Fort Collins,
Colorado 805222
Received 6 October 1999/Accepted 31 January 2000
Venezuelan equine encephalitis (VEE) virus antigenic subtypes and
varieties are considered either epidemic/epizootic or enzootic. In
addition to epidemiological differences between the epidemic and
enzootic viruses, several in vitro and in vivo laboratory markers
distinguishing the viruses have been identified, including differential
plaque size, sensitivity to interferon (IFN), and virulence for guinea
pigs. These observations have been shown to be useful predictors of
natural, equine virulence and epizootic potential. Chimeric viruses
containing variety IAB (epizootic) nonstructural genes with variety IE
(enzootic) structural genes (VE/IAB-IE) or IE nonstructural genes and
IAB structural genes (IE/IAB) were constructed to systematically
analyze and map viral phenotype and virulence determinants. Plaque size
analysis showed that both chimeric viruses produced a mean plaque
diameter that was intermediate between those of the parental strains.
Additionally, both chimeric viruses showed intermediate levels of virus
replication and virulence for guinea pigs compared to the parental
strains. However, IE/IAB produced a slightly higher viremia and an
average survival time 2 days shorter than the VE/IAB-IE virus. Finally, IFN sensitivity assays revealed that only one chimera, VE/IAB-IE, was
intermediate between the two parental types. The second chimera, containing the IE nonstructural genes, was at least five times more
sensitive to IFN than the IE parental virus and greater than 50 times
more sensitive than the IAB parent. These results implicate viral
components in both the structural and nonstructural portions of the
genome in contributing to the epizootic phenotype and indicate the
potential for epidemic emergence from the IE enzootic VEE viruses.
Venezuelan equine encephalitis (VEE)
has been an important human and equine disease for much of this
century, and recent epidemics (26, 33) clearly indicate that
VEE viruses still pose a serious public health threat. VEE viruses are
serologically classified into six distinct antigenic subtypes (31,
35). Historically, only viruses in subtype I, varieties AB and C,
are associated with major epidemics and epizootics. These antigenic
varieties have been isolated only during VEE outbreaks in human and
equine populations, with one possible exception (24). Equine
mortality due to these viruses can reach 83%; in humans, while the
mortality rate is low (<1%), neurologic disease, including
disorientation, ataxia, mental depression, and convulsions, can occur
in up to 14% of those infected (13, 33). In contrast,
viruses classified in the remaining subtypes and varieties (II to VI
and ID to IF) of the VEE antigenic complex are considered enzootic.
These viruses are usually not associated with human or equine disease,
and they circulate continually in sylvatic or swamp habitats (31,
32).
In addition to the epidemiological differences between the epidemic and
enzootic viruses, several in vitro and in vivo laboratory markers that
distinguish these viruses have been identified. Differential plaque
size was one of the first markers believed to be useful in
distinguishing epizootic and enzootic VEE virus strains (6). Epidemic IAB viruses generally produce small plaques, while plaques of
enzootic IE strains are significantly larger (19). A second marker was identified in 1974 when Calisher and Maness noted that an
enzootic IE strain of VEE virus did not kill guinea pigs when inoculated intraperitoneally (2). Specifically, the IAB
strain Trinidad donkey (TRD) killed 10 of 10 adult guinea pigs, while the IE strain 68U201 killed 0 of 10 guinea pigs when the animals were
inoculated subcutaneously (11). Subsequent studies confirmed this finding and revealed a general trend that IE strains of VEE virus
are not typically lethal in guinea pigs and produce lower viremias,
while IAB strains are highly virulent and lethal for guinea pigs
(28, 29). Additionally, the differences in guinea pig
lethality correlated with equine virulence; inbred strain 13 and
English short-hair guinea pigs survived infections with VEE viruses
that were known to be benign for equines, while equine-virulent VEE
viruses were lethal for guinea pigs (28). A third marker, sensitivity or resistance to interferon (IFN), was recently described as useful for distinguishing epizootic and enzootic VEE viruses (30). These observations have been shown to be useful
predictors of natural, equine virulence. However, no studies have been
performed to examine the molecular determinants involved in natural
equine virulence, epizootic potential, or markers of these traits. The work presented here describes an approach, using chimeric infectious clones, to systematically analyze and map viral phenotypic and virulence determinants.
Viruses.
TRD virus (subtype IAB) was used in the
construction of pVE/IC-109, which has been described elsewhere
(14). The enzootic IE sequences were derived from strain
68U201, originally isolated from a sentinel hamster near La Avellana,
Guatemala, in 1968, and subsequently passaged once in suckling mice and
twice in baby hamster kidney (BHK-21) cells. Both genomes have been
completely sequenced, and comparison of the two sequences has shown
approximately 25% nucleotide sequence divergence (16, 20).
Generation of chimeric infectious clones.
To construct the
first chimeric infectious clone, pVE/IAB-IE, two overlapping cDNA
fragments of 2.25 and 2.36 kb, covering the entire structural gene
region of the IE virus 68U201, were generated by reverse
transcription-PCR (RT-PCR). Superscript II (Gibco BRL, Gaithersburg,
Md.) was used to generate cDNA, and Pfu Turbo polymerase
(Stratagene, La Jolla, Calif.) was used for cDNA amplification (see
Table 1 for primers used). These two PCR
products were cloned into a pBluescript II SK(+) (Stratagene) shuttle
vector to produce a complete 4.4-kb subgenomic cDNA that was
subsequently transferred into the IAB infectious clone, pVE/IC-109 (Fig. 1A).
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Use of Chimeric Venezuelan Equine Encephalitis
Viruses as an Approach for the Molecular Identification of Natural
Virulence Determinants
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Primers used in the construction of chimeric and parental
infectious clones

View larger version (16K):
[in a new window]
FIG. 1.
Construction of IE and IAB VEE virus infectious
clones. Boxes containing diagonal lines represent sequences derived
from TRD, while hatched boxes contain 68U201 IE sequences. The asterisk
is the site of the MluI restriction enzyme recognition
sequence used for runoff transcription. PCR-amplified fragments (dark
bars) were inserted using the restriction enzymes indicated. (See text
for full details.) (A) Construction of pVE/IAB-IE by insertion of two
IE PCR fragments into the existing pVE/IC-109 clone. BglII
and SspI cuts were partial digests. (B) pIE/IAB was produced
by incorporation of four IE fragments into pVE/IC-109. (C) The IE
parental infectious clone was derived from pVE/IAB-IE by substitution
of 68U201 sequences from the existing IAB sequences. An additional
fragment (PshAI-Sse8387I) was required to correct
for a deletion incurred during cloning.
In vitro transcription and rescue of recombinant viruses. The parental and chimeric infectious clones were linearized with restriction endonuclease MluI to produce cDNA templates for RNA synthesis. In vitro transcription was performed as previously described (25) from the T7 RNA polymerase promoter, using an m7G(5')ppp(5')A cap analogue (New England Biolabs, Beverly, Mass.). After in vitro transcription, the RNAs were transfected into BHK-21 cells by electroporation (23). Virus was harvested after approximately 48 h when cytopathic effects (CPE) were evident in greater than 75% of the cells. Virus titers were determined by plaque assay on Vero 76 (V76) cells and reported as PFU per milliliter.
Immunofluorescence. Each rescued virus was characterized by an immunofluorescence assay using variety-specific monoclonal antibodies (MAbs) (27) to confirm the antigenic origin of the structural genes. MAb 1A1B-9 reacts with variety IE viruses but not with IAB viruses; MAb 1A3A-5 is positive for IAB but not IE viruses. These antibodies were diluted 1:400 in phosphate-buffered saline (PBS) and incubated with acetone-fixed monolayers of V76 cells that had been infected with the parental or chimeric viruses for 24 h at a multiplicity of infection of 0.1. Detection was performed with a secondary goat anti-mouse antibody conjugated to fluorescein isothiocyanate (Sigma, St. Louis, Mo.).
Plaque size analysis. The plaque phenotypes were compared essentially as described by Martin et al. (19). V76 cells were seeded into six-well tissue culture plates and allowed to grow to confluency. Tenfold dilutions of the virus were adsorbed to the monolayers for 1 h at 37°C. A 4-ml overlay consisting of minimal essential medium with 0.4% agar (Sigma) was added, and the cells were incubated at 37°C for 72 h. Agar plugs were removed, and the cells were stained with 0.25% crystal violet in 20% methanol. Approximately 15 to 30 well-isolated plaques were measured for each virus, and the means were compared by analysis of variance (ANOVA) using Bonferroni comparisons.
IFN assays.
One assay to determine the IFN sensitivity of
the parental and chimeric VEE viruses was performed, in three replicate
experiments, essentially as previously described (30).
Briefly, monolayers of L929 mouse fibroblast cells in 96-well plates
were primed with twofold dilutions of mouse IFN-
/
(Sigma),
ranging from 2,000 to 0.1 U/ml, for 24 h. After priming, 50 µl
of virus suspension (10,000 PFU/ml) was added to quadruplicate wells,
and the virus was allowed to adsorb for 1 h at 37°C. Additional
minimal essential medium supplemented with penicillin-streptomycin and
5% fetal bovine serum was added (100 µl/well). Cells were monitored
daily for signs of CPE. Controls included unprimed L929 cells infected with each virus and uninfected cells primed with IFN. Final
determination of the concentration of IFN inhibiting 50% of the CPE
was made on day 5 postinfection. Additionally, to corroborate the
results obtained using the IFN sensitivity assay described in the
literature (30), assays were performed to determine the
titer of virus being produced at selected IFN concentrations. Duplicate
25-cm2 flasks of L929 cells were induced with 0, 0.1, or 10 U of IFN-
/
per ml 24 h prior to infection with 2 × 105 PFU of one of the four parental or chimeric viruses. At
1 and 3 days, 0.5-ml aliquots of supernatant were removed and analyzed by plaque assay to determine viral titer. Both titers and IFN resistance endpoints were statistically compared by ANOVA.
Guinea pig virulence. Stocks of parental IE and IAB viruses as well as chimeric IAB/IE and IE/IAB viruses were inoculated into 3- to 5-week-old (300- to 500-g) English short-hair guinea pigs. A 0.2-ml aliquot of each virus (1,000 to 100,000 PFU), diluted in PBS, was injected subcutaneously. Serum (20 µl) was collected daily by the saphenous vein method (9) for 5 days, and the titer of virus in the blood determined by plaque assay. Animals were observed twice daily for signs of infection, and mean day of death was documented. Average survival time and virus titer (which was affected by variable group size due to mortality during the course of the study) were statistically compared using a one-way ANOVA and a two-way ANOVA or general linear model, respectively.
| |
RESULTS |
|---|
|
|
|---|
Generation and rescue of recombinant viruses. Previous studies have proposed that viral genetic elements contributing to vector specificity or conferring subtype characteristics may be expressed from both the nonstructural and structural gene regions. In an attempt to broadly define putative virulence genes and identify possible multigenic determinants, chimeric IE and IAB variety viruses were engineered to contain reciprocal combinations of the entire structural gene region of one variety of virus with the nonstructural genes of the other variety (Fig. 1).
Chimera pVE/IAB-IE was constructed to contain the IAB nonstructural genes with the IE structural genes, while the counterpart to this first construct, pIE/IAB, contained the IE nonstructural genes and the IAB structural genes. Both chimeric viruses reacted as expected antigenically; fluorescence was detected in VE/IAB-IE virus-infected BHK-21 cells using the IE virus-specific MAb 1A1B-9, while a MAb specific for variety IAB, IC, and subtype II viruses (MAb 1A3A-5) showed no immunofluorescence. Conversely, the IE/IAB virus-infected cells demonstrated only 1A3A-5 MAb-specific immunofluorescence.Plaque size analysis.
Size determination plaque assays were
performed to compare the recombinant chimeric viruses with both
parental strains. Although individual viruses typically produced a
mixed-plaque size phenotype, the parental epizootic strain produced
significantly smaller plaques than the enzootic IE parent. The average
plaque sizes (± standard deviation) were as follows: VE/IC-109 (IAB
parental), 3.3 ± 1.1 mm; IE.AA (IE parental), 5.5 ± 0.4 mm;
VE/IAB-IE (chimera), 4.6 ± 0.7 mm; and IE/IAB (chimera), 4.5 ± 0.6 mm (Table 2). The mean plaque
diameters of both chimeric viruses were intermediate between those of
the parental strains, and comparison of the means indicated that both
chimeras produced an average plaque size that was significantly different from that of the IAB and IE parental strains (all
P values < 0.005).
|
IFN sensitivity.
A correlation between virulence of a given
VEE virus strain and its sensitivity or resistance to IFN has been well
established (10, 30). This same approach was used with the
viruses in this study; the parental IAB strain (VE/IC-109) was the most
resistant to IFN-
/
(50% protective dose = 5.6 U), while the
IE parental virus (IE.AA) was extremely sensitive to induction with
IFN-
/
(50% protective dose = 0.4 U) (Table 2). One chimera,
VE/IAB-IE, was intermediate between the two parental types but still
quite resistant to IFN (50% protective dose = 2.3 U).
Interestingly, the chimera containing the IE nonstructural genes was at
least as sensitive to IFN-
/
as the IE parental virus (50%
protective dose < 0.1 U). Statistical analysis of variance
indicated that the VE/IC-109 parent was significantly different from
the IE/IAB chimera (P < 0.03) and that the IE.AA
parent was significantly different from the VE/IAB-IE chimera
(P < 0.05). Additional VEE virus isolates that had
been previously characterized by the IFN sensitivity technique were
assayed here to confirm the reproducibility of the test. Strains Fe3-7c
(Everglades, subtype II) and 93-42124 (subtype IE) were categorized as
sensitive and resistant, respectively, with 50% inhibition endpoints
at <0.01 U/ml (Fe3-7c) and 26 U/ml (93-42124). The IFN sensitivity
classifications assigned to these two virus strains corresponded to
those previously determined (30), although all VEE viruses
were more sensitive to IFN-
/
in this report.
/
per ml. At the 50% endpoint doses,
none of the viruses were significantly different, with titers ranging
from 3.0 to 5.7 log10 50% tissue culture infective
doses/ml. Determination of viral titers at the defined IFN-
/
doses of 10 and 0.1 U/ml confirmed the results of the IFN sensitivity
assay; each parental virus was significantly different (P
<0.05) from the chimeric virus containing the structural genes of
that parent (Table 2).
Virulence for guinea pigs.
Outbred guinea pigs were infected
with each of the viruses by subcutaneous inoculation, and daily serum
samples were used to determine the viremia throughout the course of
infection (Fig. 2). The clone-derived IAB
virus was by far the most virulent in guinea pigs (Table 2 and Fig. 2).
It produced a very high titered (4.6 to 6.3 log10 PFU/ml),
rapid viremia that consistently killed the animals in only 3 to 4 days.
In contrast, the IE parental virus was avirulent; animals infected with
this virus exhibited few clinical signs of illness, produced a
low-titered viremia (2.8 to 3.5 log10 PFU/ml) that was
cleared within 3 days, and subsequently recovered from the infection.
Guinea pigs receiving either VE/IAB-IE or IE/IAB virus showed
intermediate levels of virus replication and virulence, both being
statistically different from the IE parent in average survival time
(P < 0.01) and, at later time points, guinea pig
viremia (P < 0.02 at 96 h). Neither chimera
differed significantly from the IAB parent for guinea pig viremia
(P = 0.06 to 0.36); however, the VE/IAB-IE chimera had
an average survival time statistically different from that of VE/IC-109
(P = 0.03). The IE/IAB chimeric virus appeared to be
more virulent than the reciprocal chimera (3.9 to 6.0 log10 and 3.8 to 4.6 log10 PFU/ml, respectively). Both chimeras
were lethal for guinea pigs; however, the IE/IAB virus produced a
slightly higher viremia and resulted in an average survival time that
was 2 days shorter than that of the VE/IAB-IE virus.
|
| |
DISCUSSION |
|---|
|
|
|---|
Determination of the molecular basis of reemergence of VEE epidemics and epizootics, as well as the differential virulence of the epizootic and enzootic viruses, are significant issues in arbovirology. Previous studies have shown that laboratory mutations in the VEE virus genome can lead to altered ability to efficiently infect and disseminate in mosquitoes (34) and mice (4), change cell type specificity (20), and generate viral phenotypic changes (5, 7, 12). However, determinants of the viral genome directly involved in natural virulence have not yet been elucidated. Using a molecular genetic approach exploiting infectious clone technology, we determined that viral genetic determinants in both the structural and nonstructural gene regions are involved in natural enzootic versus epizootic virulence.
Most studies concerning the role of VEE viral genetics in virulence have focused on the structural proteins, in particular, the surface glycoproteins. A single mutation in the E2 glycoprotein of the TRD strain delayed replication of the mutant in mice by almost 2 days and significantly reduced the pathogenicity of the virus (4). Interestingly, because the envelope proteins are in close association with each other as a dimeric spike structure in the mature virion (1, 22), Davis and colleagues (3) showed that attenuating mutations in E2 glycoprotein could be compensated for by changes in the E1 protein.
The E2 protein is also important in infection of the insect vector. One MAb-resistant mutant, containing a single mutation in E2, was restricted in its ability to disseminate from the mosquito midgut following oral infection. Dissemination of this mutant was identical to that of the wild-type virus when inoculated into mosquitoes, suggesting that the level of inhibition was the viral entry into midgut epithelial cells (34).
More recently, mutations leading to attenuation of the VEE virus TRD strain to generate the TC-83 vaccine strain were identified (14). A major determinant of attenuation occurred at amino acid position E-120 in the E2 glycoprotein gene. Incorporation of an additional mutation at genome nucleotide position 3 in the 5' noncoding region (NCR) significantly enhanced the attenuated character of the vaccine strain. The results of our work contrasting enzootic IE and epizootic IAB strains corroborated this finding. The chimeric IE/IAB virus, containing the virulent IAB structural genes, demonstrated an intermediate mean plaque size, an increased resistance to IFN, and an increase in guinea pig virulence compared to the wild-type IE parent. These findings support the hypothesis that a major virulence determinant is present in the structural gene region, perhaps being enhanced by components of the nonstructural or 5' noncoding regions of the genome. However, Kinney et al. (14) found that incorporation of the TRD nucleotide in the 5' NCR into the TC-83 infectious clone by itself was insufficient to generate the virulent phenotype; the mutation in the E2 gene was required in concert to show any alteration in virulence. The phenotype of the VE/IAB-IE virus seems to contradict this finding. This virus does not maintain the IE-like characteristics as would be expected if mutations in the E2 gene were absolutely essential for virulence. The VE/IAB-IE virus was markedly different from the IE parent in ability to replicate in the guinea pig model (Table 1 and Fig. 2). In fact, this virus exhibited a mortality pattern in guinea pigs that was more similar to that of the virulent IAB parent virus than the avirulent IE parent, suggesting that a component present in the 5' NCR or the nonstructural genes is an additional major determinant of viral pathogenesis. It is important to note that the information derived from the TRD parent-TC-83 derivative comparison, a pair containing only 11 differences in the entire genome (15), is merely a point to begin comparisons between the wild-type virulence determinants of IAB versus IE viruses, which involve many more genetic differences that may have profound effects on viral phenotype. Because protein products from both the alphaviral structural and nonstructural regions interact with sequence domains in the other region, the 25% sequence divergence between the IE and IAB viruses may result in less competent chimeras, thus limiting the utility of the large-gene-region chimeric viruses. However, chimeric alphaviruses have previously been shown to be useful for studies of viral replication and recombination (8, 17). In this study, because both VEE virus chimeras demonstrated increased competence and virulence compared to the IE parent, our results reveal that chimeric infectious clones can provide valuable insight into the potential for a given gene region to contain virulence determinants.
One potential candidate for a nonstructural protein involved in VEE virulence is nsP3, which contains an extremely hypervariable region in its carboxy-terminal region (20). The nsP3 gene has been shown to tolerate numerous mutations, including large deletions, and still produce viable virus particles in vertebrate cells. Interestingly, some nsP3 mutations in another alphavirus, Sindbis virus, while doing little to impair replication in mammalian cells, significantly reduced the replicative ability of the virus in mosquito cells (18). Presumably, if the nsP3 gene is involved in virulence, it could require additional mutations to completely alter the virulence phenotype since no difference in virulence in mice was noted for a TC-83 vaccine strain derivative that contained the wild-type TRD nsP3 sequences (14). However, this would not be unexpected based on our results demonstrating that intermediate virulence and pathogenicities were observed for both the VE/IAB-IE and the IE/IAB viruses.
Finally, it is important to note that the three different virulence
markers used in this study, differential plaque size, sensitivity to
IFN, and virulence for guinea pigs, may assess very different aspects
of viral virulence. These markers were chosen because they have
previously been shown to distinguish between epizootic and enzootic VEE
virus strains, but they are unlikely to separate them based on the same
mechanisms. Plaque size, for example, is likely to be a reflection of
the surface charge of the glycoproteins as the viral particles move
through an unpurified agar overlay containing polyanions that may bind virus, thus affecting mobility but not binding or entry into the cell
(13, 19). Assays such as IFN sensitivity and guinea pig virulence are more likely to distinguish the epizootic and enzootic strains based on biological or epidemiological differences.
Interestingly, the IE/IAB results presented here indicate that even
these two methods of phenotype characterization may employ different
mechanisms. The IE/IAB virus, containing the virulent IAB structural
genes, was more virulent in guinea pigs than its counterpart but was just as sensitive to IFN-
/
(producing the same titers in the presence of IFN) as the IE parental strain. This could imply that while
IFN-
/
may modulate VEE virus pathogenesis, it may not be the
dominant mechanism of protection from infection in guinea pigs and
possibly equines.
Most importantly, it is clear that the enzootic IE VEE viruses, which had previously been considered to have no equine virulence, may indeed possess some epidemic potential in both the structural and nonstructural portions of the genome. This is a significant finding considering that in 1993 and 1996, IE VEE viruses caused outbreaks of equine encephalitis in southern Mexico, with over 160 cases documented (21). Utilizing multiple approaches to characterize genotypic markers associated with virulence, chimeric viruses should be a useful approach for elucidating genetic determinants involved in pathogenesis, transmission, and evolution of the multiple subtypes and varieties of the VEE antigenic complex. Construction of additional chimeras with this system, as well as using more closely related VEE viruses, to investigate progressively more defined viral genetic elements will eventually provide a better understanding of the mechanisms of VEE virus virulence.
| |
ACKNOWLEDGMENTS |
|---|
We thank Jonathan Smith and Bruce Crise for helpful discussions during the course of these studies and Daniel Freeman for assistance with statistical analyses.
This research was supported in part by grant AI-10984 from the National Institutes of Health and by the John D. and Catherine T. MacArthur Foundation. A. M. Powers was supported by the James W. McLaughlin Fellowship Fund. A. C. Brault was supported by NIH emerging tropical diseases T32 grant AI107526.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathology & Center for Tropical Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609. Phone: (409) 747-2440. Fax: (409) 747-2415. E-mail: ampowers{at}utmb.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Anthony, R. P., and D. T. Brown.
1991.
Protein-protein interactions in an alphavirus membrane.
J. Virol.
65:1187-1194 |
| 2. | Calisher, C. H., and K. C. Maness. 1974. Virulence of Venezuelan equine encephalomyelitis virus subtypes for various laboratory hosts. Appl. Microbiol. 28:881-884[Medline]. |
| 3. | Davis, N. L., K. W. Brown, G. F. Greenwald, A. J. Zajac, V. L. Zacny, J. F. Smith, and R. E. Johnston. 1995. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212:102-110[CrossRef][Medline]. |
| 4. | Davis, N. L., F. B. Grieder, J. F. Smith, G. F. Greenwald, M. L. Valenski, D. C. Sellon, P. C. Charles, and R. E. Johnston. 1994. A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis. Arch. Virol. 9:99-109[CrossRef]. |
| 5. | Davis, N. L., P. Powell, G. F. Greenwald, L. V. Willis, B. J. B. Johnson, J. F. Smith, and R. E. Johnston. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length clone. Virology 183:20-31[CrossRef][Medline]. |
| 6. |
Franck, P. T., and K. M. Johnson.
1971.
An outbreak of Venezuelan equine encephalomeylitis in Central America. Evidence for exogenous source of a virulent virus subtype.
Am. J. Epidemiol.
94:487-495 |
| 7. | Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206:994-1006[CrossRef][Medline]. |
| 8. |
Hahn, C. S.,
S. Lustig,
E. G. Strauss, and J. H. Strauss.
1988.
Western equine encephalitis virus is a recombinant virus.
Proc. Natl. Acad. Sci. USA
85:5997-6001 |
| 9. |
Hem, A.,
A. J. Smith, and P. Solberg.
1998.
Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink.
Lab. Anim.
32:364-368 |
| 10. |
Jahrling, P. B.,
E. Dendy, and G. A. Eddy.
1974.
Correlates to increased lethality of attenuated Venezuelan encephalitis virus vaccine for immunosuppressed hamsters.
Infect. Immun.
9:924-930 |
| 11. |
Jahrling, P. B., and G. A. Eddy.
1977.
Comparisons among members of the Venezuelan encephalitis virus complex using hydroxylapatite column chromatography.
Am. J. Epidemiol.
106:408-417 |
| 12. |
Johnson, B. J.,
R. M. Kinney,
C. L. Kost, and D. W. Trent.
1986.
Molecular determinants of alphavirus neurovirulence: nucleotide and deduced protein sequence changes during attenuation of Venezuelan equine encephalitis virus.
J. Gen. Virol.
67:1951-1960 |
| 13. | Johnson, K. M., and D. H. Martin. 1974. Venezuelan equine encephalitis. Adv. Vet. Sci. Comp. Med. 18:79-116[Medline]. |
| 14. |
Kinney, R. M.,
G. J. Chang,
K. R. Tsuchiya,
J. M. Sneider,
J. T. Roehrig,
T. M. Woodward, and D. W. Trent.
1993.
Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein.
J. Virol.
67:1269-1277 |
| 15. | Kinney, R. M., B. J. Johnson, J. B. Welch, K. R. Tsuchiya, and D. W. Trent. 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 170:19-30[CrossRef][Medline]. |
| 16. |
Kinney, R. M.,
K. R. Tsuchiya,
J. M. Sneider, and D. W. Trent.
1992.
Molecular evidence for the origin of the widespread Venezuelan equine encephalitis epizootic of 1969 to 1972.
J. Gen. Virol.
73:3301-3305 |
| 17. | Kuhn, R. J., D. E. Griffin, K. E. Owen, H. G. Niesters, and J. H. Strauss. 1996. Chimeric Sindbis-Ross River viruses to study interactions between alphavirus nonstructural and structural regions. J. Virol. 70:7900-7909[Abstract]. |
| 18. | Lastarza, M. W., A. Grakoui, and C. M. Rice. 1994. Deletion and duplication mutations in the C-terminal nonconserved region of Sindbis virus nsP3: effects on phosphorylation and on virus replication in vertebrate and invertebrate cells. Virology 202:224-232[CrossRef][Medline]. |
| 19. | Martin, D. H., W. H. Dietz, O. Alvaerez, Jr., and K. M. Johnson. 1982. Epidemiological significance of Venezuelan equine encephalomyelitis virus in vitro markers. Am. J. Trop. Med. Hyg. 31:561-568. |
| 20. | Oberste, M. S., M. D. Parker, and J. F. Smith. 1996. Complete sequence of Venezuelan equine encephalitis virus subtype IE reveals conserved and hypervariable domains within the C terminus of nsP3. Virology 219:314-320[CrossRef][Medline]. |
| 21. | Oberste, M. S., S. M. Schmura, S. C. Weaver, and J. F. Smith. 1999. Geographic distribution of Venezuelan equine encephalitis virus subtype IE genotypes in Central America and Mexico. Am. J. Trop. Med. Hyg. 60:630-634[Abstract]. |
| 22. |
Paredes, A. M.,
D. T. Brown,
R. Rothnagel,
W. Chiu,
R. J. Schoepp,
R. E. Johnston, and B. V. Prasad.
1993.
Three-dimensional structure of a membrane-containing virus.
Proc. Natl. Acad. Sci. USA
90:9095-9099 |
| 23. |
Powers, A. M.,
K. I. Kamrud,
K. E. Olson,
S. Higgs,
J. O. Carlson, and B. J. Beaty.
1996.
Molecularly engineered resistance to California serogroup virus replication in mosquito cells and mosquitoes.
Proc. Natl. Acad. Sci. USA
93:4187-4191 |
| 24. | Powers, A. M., M. S. Oberste, A. C. Brault, R. Rico-Hesse, S. M. Schmura, J. F. Smith, W. Kang, W. P. Sweeney, and S. C. Weaver. 1997. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J. Virol. 71:6697-6705[Abstract]. |
| 25. | Powers, A. M., K. E. Olson, S. Higgs, J. O. Carlson, and B. J. Beaty. 1994. Intracellular immunization of mosquito cells to LaCrosse virus using a recombinant Sindbis virus vector. Virus Res. 32:57-67[CrossRef][Medline]. |
| 26. |
Rico-Hesse, R.,
S. C. Weaver,
J. de Siger,
G. Medina, and R. A. Salas.
1995.
Emergence of a new epidemic/epizootic Venezuelan equine encephalitis virus in South America.
Proc. Natl. Acad. Sci. USA
92:5278-5281 |
| 27. | Roehrig, J. T., and R. A. Bolin. 1997. Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype I Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay. J. Clin. Microbiol. 35:1887-1890[Abstract]. |
| 28. | Scherer, W. F., and J. Chin. 1977. Responses of guinea pigs to infections with strains of Venezuelan encephalitis virus, and correlations with equine virulence. Am. J. Trop. Med. Hyg. 26:307-312. |
| 29. | Scherer, W. F., J. Chin, and J. V. Ordonez. 1979. Further observations on infections of guinea pigs with Venezuelan encephalitis virus strains. Am. J. Trop. Med. Hyg. 28:725-728. |
| 30. |
Spotts, D. R.,
R. M. Reich,
M. A. Kalkhan,
R. M. Kinney, and J. T. Roehrig.
1998.
Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5' noncoding region and glycoproteins.
J. Virol.
72:10286-10291 |
| 31. | Walton, T. E., and M. A. Grayson. 1988. Venezuelan equine encephalomyelitis, p. 203-233. In T. P. Monath (ed.), The arboviruses: epidemiology and ecology, vol. IV. CRC Press, Boca Raton, Fla. |
| 32. | Weaver, S. C., L. A. Bellew, and R. Rico-Hesse. 1992. Phylogenetic analysis of alphaviruses in the Venezuelan equine encephalitis complex and identification of the source of epizootic viruses. Virology 191:282-290[CrossRef][Medline]. |
| 33. | Weaver, S. C., R. Salas, R. Rico-Hesse, G. V. Ludwig, M. S. Oberste, J. Boshell, and R. B. Tesh. 1996. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 348:436-440[CrossRef][Medline]. |
| 34. |
Woodward, T. M.,
B. R. Miller,
B. J. Beaty,
D. W. Trent, and J. T. Roehrig.
1991.
A single amino acid change in the E2 glycoprotein of Venezuelan equine encephalitis virus affects replication and dissemination in Aedes aegypti mosquitoes.
J. Gen. Virol.
72:2431-2435 |
| 35. |
Young, N. A., and K. M. Johnson.
1969.
Antigenic variants of Venezuelan equine encephalitis virus: their geographic distribution and epidemiologic significance.
Am. J. Epidemiol.
89:286-307 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|